In this Issue
From materials to referrals, a look at what's driving today's practice patterns.
Chief Medical Editor’s Page
By Barry T. Katzen, MD
Clinical indicators and arterial embolization techniques.
By Jason Salsamendi, MD; David Quintana, MD; Issam Kably, MD; and Govindarajan Narayanan, MD
A technical guide describing the uses of this technique in interventional radiology and oncology procedures.
By Aaron M. Fischman, MD, and Rahul S. Patel, MD
Approaches, techniques, and sclerosing and embolic agents that can be used in low- and high-flow vascular malformations.
By Guilherme Dabus, MD, and James F. Benenati, MD
John H. Fischer II, MD, discusses why it’s important, what works, and what doesn’t.
Does Material Matter?
The background, available options, and ideal applications of particulate embolics.
By Marcelo Guimaraes, MD; David Arrington, MD; Timothy MacFall, MD; Ricardo Yamada, MD; and Claudio Schönholz, MD
The history behind absolute ethanol as an intravascular embolic agent, its mechanism of action, and applications of its use.
By Wayne F. Yakes, MD, FSIR, FCIRSE
Deciding which modalities to use for determining patient candidacy, procedural planning, course, and follow-up.
By Jose I. Almeida, MD, FACS, RPVI, RVT
Spurring the next wave of superficial venous disease therapies.
By Steve Elias, MD, FACS
Utilizing endovascular venoplasty for central venous occlusion through a single infraclavicular incision to manage superior vena cava syndrome.
By Sean O’Neill, MD; Issam Kably, MD; and Govindarajan Narayanan, MD
Featured TechnologySponsored by Penumbra, Inc.
Case reports illustrating the utility of this novel technology.
By Claudio Schönholz, MD; James F. Benenati, MD; Frank Arko, MD; Corey Teigen, MD; and J David Moskovitz, MD
Coding & Reimbursement
Several families of codes for endovascular/interventional procedures have changed as part of the AMA’s ongoing effort to bundle and reassess relative valuation of all CPT codes.
By Katharine L. Krol, MD, FSIR, FACR
An expert vascular surgeon details his approaches to managing type II endoleaks and asymptomatic carotid artery stenosis and shares his thoughts on regulation, reimbursement, and the future of stem cell therapy for CLI.